Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting, 65184-65185 [2023-20390]
Download as PDF
<![CDATA[
65184
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
Drive, Room 6164, Bethesda, MD 20892,
(301) 435–1044, chenhui@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20437 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; K99–U24–R13 SEP.
Date: November 3, 2023.
Time: 2:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8823, wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel SEP–1 K99 HG013541–01 Member
Conflict.
Date: November 3, 2023.
Time: 6:15 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8823, wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Diversity Centers.
Date: November 16, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8739, pozzattr@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 18, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20490 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 18, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20492 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on
November 16, 2023. The topic for this
meeting will be ‘‘The Application of
Digital Health Technology to Type 2
Diabetes Management: Current Status,
Research Gaps, and Opportunities’’. The
meeting is open to the public.
DATES: The meeting will be held on
November 16, 2023 from 12:00 p.m. to
4:00 p.m. EST.
ADDRESSES: The meeting will be held
via the Zoom online video conferencing
platform. For details, and to register,
please contact dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda,
which will be posted when available,
see the DMICC website,
www.diabetescommittee.gov, or contact
Dr. William Cefalu, Executive Secretary
of the Diabetes Mellitus Interagency
Coordinating Committee, National
Institute of Diabetes and Digestive and
Kidney Diseases, 6707 Democracy
Boulevard, Democracy 2, Room 6037,
Bethesda, MD 20892, telephone: 301–
435–1011; email: dmicc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 42 U.S. Code 285c–3,
the DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, And Blood
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence Study
Section.
Date: November 16–17, 2023.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Canopy by Hilton, Washington,
DC, Bethesda North, 940 Rose Avenue, North
Bethesda, MD 20892 (Hybrid Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
E:\FR\FM\21SEN1.SGM
21SEN1
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
November 16, 2023 DMICC meeting will
focus on ‘‘The Application of Digital
Health Technology to Type 2 Diabetes
Management: Current Status, Research
Gaps, and Opportunities.’’
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 5
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
website, www.diabetescommittee.gov.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology,
and Metabolic Diseases, National Institute of
Diabetes and Digestive and Kidney Diseases,
and Metabolic Diseases, National Institutes
of Health.
[FR Doc. 2023–20390 Filed 9–20–23; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2023 Notice of
Supplemental Funding Opportunity
Substance Abuse and Mental
Health Services Administration,
AGENCY:
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
Department of Health and Human
Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) is proposing to provide oneyear supplemental funding in FY 2023
to three Hawaii grant programs to
support Maui residents in the aftermath
of the Maui wildfires. The Hawaii State
Department of Health, the recipient for
Certified Community Behavioral Health
Clinics Planning, Development, and
Implementation (CCBHC–PDI), Grants
for Expansion and Sustainability of the
Comprehensive Community Mental
Health Services for Children with
Serious Emotional Disturbances
Program (CMHI), and Community
Mental Health Services Block Grant
(MHBG) will be offered a total of
$2,765,556 in supplemental funding
since they are the only recipient
providing or able to provide services to
Maui residents.
FOR FURTHER INFORMATION CONTACT:
Tison Thomas, Deputy Director, Center
for Mental Health Services/SAMHSA,
Tison.thomas@samhsa.hhs.gov; 202–
853–5282.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: FY 2022
Certified Community Behavioral Health
Clinics Planning, Development, and
Implementation Grants (CCBHC–PDI),
SM–22–022; FY 2023 Community
Mental Health Services Block Grant
(MHBG); FY 2020 Grants for Expansion
and Sustainability of the
Comprehensive Community Mental
Health Services for Children with
Serious Emotional Disturbances (CMHI).
Assistance Listing Number: 93.696—
CCBHC–PDI; 93.104—CMHI; 93.958—
MHBG.
Authority: CCBHC–PDI grants are
authorized under Section 520A of the
Public Health Services Act, as amended.
CMHI grants are authorized under
Sections 516–565 of the Public Health
Services Act, as amended. MHBG grants
are authorized under Section 1920 of
the Public Health Service Act, as
amended.
Justification: Eligibility for this
supplemental funding is limited to the
Hawaii State Department of Health as
the grant recipient for the CCBHC–PDI,
CMHI and MHBG programs. They are
the only Hawaii funded recipient within
these programs and are providing or
able to provide services to Maui
residents. This supplemental funding
will be used to address the behavioral
health needs of Maui residents in the
SUMMARY:
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
65185
aftermath of the Maui wildfires. This is
not a formal request for application.
Assistance will only be provided to the
Hawaii State Department of Health
based on the receipt of a satisfactory
application and associated budget.
Dated: September 15, 2023.
Ann Ferrero,
Public Health Analyst.
[FR Doc. 2023–20432 Filed 9–20–23; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2010–0164]
National Boating Safety Advisory
Committee; October 17, 2023 Virtual
Meeting
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Notice of Federal advisory
committee virtual meeting.
AGENCY:
The National Boating Safety
Advisory Committee (Committee) and
its Subcommittees will meet virtually to
discuss matters relating to national
boating safety. The virtual meeting will
be open to the public.
DATES:
Meeting: The Committee and its
Subcommittees will meet on Tuesday,
October 17, 2023, from noon until 4
p.m. Eastern Standard Time (EST). This
virtual meeting may adjourn early if the
Committee has completed its business.
Comments and supporting
documentation: To ensure your
comments are received by Committee
members before the virtual meeting,
submit your written comments no later
than October 11, 2023.
ADDRESSES: To join the virtual meeting
or to request special accommodations,
contact the individual listed in the FOR
FURTHER INFORMATION CONTACT section
no later than 1 p.m. EST on October 16,
2023. The number of virtual lines are
limited and will be available on a firstcome, first-served basis.
Pre-registration information: Preregistration is required for attending this
virtual meeting. You must request
attendance by contacting the individual
listed in the FOR FURTHER INFORMATION
CONTACT section of this notice. You will
receive a response with attendance
instructions.
The National Boating Safety Advisory
Committee is committed to ensuring all
participants have equal access
regardless of disability status. If you
require reasonable accommodation due
SUMMARY:
E:\FR\FM\21SEN1.SGM
21SEN1
]]>Agencies
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Pages 65184-65185]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20390]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a meeting on November 16, 2023. The topic for this
meeting will be ``The Application of Digital Health Technology to Type
2 Diabetes Management: Current Status, Research Gaps, and
Opportunities''. The meeting is open to the public.
DATES: The meeting will be held on November 16, 2023 from 12:00 p.m. to
4:00 p.m. EST.
ADDRESSES: The meeting will be held via the Zoom online video
conferencing platform. For details, and to register, please contact
[email protected].
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, including a draft agenda, which will be posted when
available, see the DMICC website, www.diabetescommittee.gov, or contact
Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus
Interagency Coordinating Committee, National Institute of Diabetes and
Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2,
Room 6037, Bethesda, MD 20892, telephone: 301-435-1011; email:
[email protected].
SUPPLEMENTARY INFORMATION: In accordance with 42 U.S. Code 285c-3, the
DMICC, chaired by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising members of the Department of Health
and Human Services and other federal agencies that support diabetes-
related
[[Page 65185]]
activities, facilitates cooperation, communication, and collaboration
on diabetes among government entities. DMICC meetings, held several
times a year, provide an opportunity for Committee members to learn
about and discuss current and future diabetes programs in DMICC member
organizations and to identify opportunities for collaboration. The
November 16, 2023 DMICC meeting will focus on ``The Application of
Digital Health Technology to Type 2 Diabetes Management: Current
Status, Research Gaps, and Opportunities.''
Any member of the public interested in presenting oral comments to
the Committee should notify the contact person listed on this notice at
least 5 days in advance of the meeting. Interested individuals and
representatives or organizations should submit a letter of intent, a
brief description of the organization represented, and a written copy
of their oral presentation in advance of the meeting. Only one
representative of an organization will be allowed to present; oral
comments and presentations will be limited to a maximum of 5 minutes.
Printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
Committee by forwarding their statement to the contact person listed on
this notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person. Because of time constraints for the meeting,
oral comments will be allowed on a first-come, first-serve basis.
Members of the public who would like to receive email notification
about future DMICC meetings should register for the listserv available
on the DMICC website, www.diabetescommittee.gov.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases,
National Institute of Diabetes and Digestive and Kidney Diseases, and
Metabolic Diseases, National Institutes of Health.
[FR Doc. 2023-20390 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
